Home diagnostic MIT-based biotechnology firm developing nanoSPLASH, a saliva-based home diagnostic test with rapid results. Opportunity for partnerships or pilot programs with consumer health retailers, at-home testing distributors, and direct-to-consumer platforms seeking rapid PCR-like home tests.

Early-stage growth Revenue currently in the 1M–10M range and a small to mid-sized team (11–50 employees). Potential for channel partnerships with larger biotech distributors, contract research organizations, and strategic investors looking to accelerate scale and go-to-market capabilities.

Tech-enabled Tech stack includes e-commerce and payments platforms (Shopify, Apple Pay, Google Pay, PayPal, Venmo) and developer tools (Node.js). Leverage this to accelerate B2C rollout, manage digital marketing, and enable frictionless online purchase and subscription models for at-home testing.

Strategic fit Positioned in biotechnology research with a focus on rapid diagnostics. Attractive for partnerships with healthcare providers, telemedicine platforms, and ecosystems seeking to integrate rapid home-testing into patient care pathways.

Competitive landscape Comparable peers show scale and higher revenue in adjacent markets; opportunities exist to differentiate through speed of results, ease of use, and integration with existing patient data workflows. Potential to target customers from consumer health to enterprise health plans.